A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Myasthenia Gravis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 12 (planned)
- Started
- Jul 20, 2022
- Main results expected
- Jun 30, 2027
- Fully finished
- Jul 2, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline in Total Serum Immunoglobulin-G (IgG) Levels
Measured over: Up to 3 years
Number of Participants with Infectious Adverse Events (AEs)
Measured over: Up to 3 years
Number of Participants with Serious AEs (SAEs)
Measured over: Up to 3 years
Number of Participants with Adverse Events of Special Interests (AESIs)
Measured over: Up to 3 years
Number of Participants with Abnormalities in Clinical Laboratory Tests
Measured over: Up to 3 years
Number of Participants with Abnormalities in Vital Signs
Measured over: Up to 3 years
Number of Participants with Abnormalities in Physical Examination
Measured over: Up to 3 years
Serum Concentration of Nipocalimab over Time
Measured over: Up to 3 years
Clearance (CL) of Nipocalimab
Measured over: Up to 3 years
Volume of Distribution (V) of Nipocalimab
Measured over: Up to 3 years
Half-life (t1/2) of Nipocalimab
Measured over: Up to 3 years
Steady-state Peak Concentration (Cpeak,ss) of Nipocalimab
Measured over: Up to 3 years
Steady-state Trough concentration (Ctrough,ss) of Nipocalimab
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05265273 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC